NOVOS Core Trial Shows Vascular Gains in Healthy Adults
Supplements

NOVOS Core Trial Shows Vascular Gains in Healthy Adults

By Dr. Elena Voss · · 2 min read

Vascular Benefits Without Lipid Changes

A six-month randomized controlled trial at the University of Surrey found that daily NOVOS Core improved endothelial function and reduced arterial stiffness in healthy adults. The study also reported lower systolic blood pressure. These results were published in the European Heart Journal Open. The trial used a double-blind, placebo-controlled design to isolate the supplement’s effect.

The research focused on vascular health markers that predict long-term cardiovascular risk. Participants took the supplement for 180 days. Researchers measured flow-mediated dilation and arterial pulse wave velocity. Both metrics improved significantly compared to the placebo group. Systolic pressure dropped, indicating a direct hemodynamic benefit.

The trial revealed a clear separation between vascular function and lipid levels. While arteries became more compliant and pressure fell, cholesterol and triglyceride concentrations remained unchanged. This suggests the supplement acts on the vessel wall itself rather than on fat metabolism. Endothelial cells responded to the intervention, but the blood’s lipid profile did not.

Does Lower Pressure Mean Lower Risk?

Supplements often promise broad metabolic fixes. This study shows a more targeted effect. The vascular improvements were statistically significant. However, the lack of lipid movement means the product does not treat hyperlipidemia. It supports vessel health, not fat clearance.

The drop in systolic pressure is clinically meaningful. Even small reductions in blood pressure reduce stroke and heart attack risk. The trial participants were healthy adults, so baseline pressure was already normal. The observed drop suggests the supplement can optimize vascular tone. It does not treat hypertension, but it may prevent pre-hypertension from progressing.

Researchers noted that the double-blind design minimized bias. The placebo group showed no change, confirming the effect was not psychological. The vascular gains were consistent across all measured endpoints. This consistency strengthens the claim that NOVOS Core has a real physiological impact.

Frequently Asked Questions

Did the trial show any lipid changes? No. Lipid levels remained stable throughout the six-month period. The supplement improved vessel function without altering cholesterol or triglycerides.

How long did participants take the supplement? Participants took NOVOS Core daily for six months. The trial duration was sufficient to detect changes in arterial stiffness and blood pressure.

Was the study double-blind? Yes. Both participants and researchers were blinded to group assignment. This design helps ensure the results reflect the supplement’s true effect, not expectation.

Leave a comment

Every comment is read before it goes live. You will see it published once approved. You can send at most 2 comments per hour.